If you have to think if this is a good entry point, then you don’t know what you’re buying. The CEO clearly stated that the virtually risk-free (according to Perry) 7 billion market opportunity is expected to start bringing in the dough within the next 18-24 months. He used words like “when we get FDA approval” instead of “if we get FDA approval.” He clearly laid out in his webinar that the SP will end up looking like a hockey stick from these levels. Two years from greatly increasing revenues could easily lead to a 5-Disallowed from these obscenely inexpensive shares within 3 years. —That’s potentially 10 times your investment within just a few years. If you think it’s not possible, then I would advise to simply look at the 5 year chart. Believe me, it’s possible AND likely. The sector as a whole is down, yet the market cap is very low considering the total $22 billion opportunity in the pipeline. Recell is like the invention of the wheel and just as life-changing for many people AND animals. More indications are likely to come in the long term thus further increasing the potential market opportunity. This is proven, FDA-approved biotechnology, and discounting cash from the market cap leaves only a small amount of investment into growth. This IS NOT too good to be true, and believe me, if you are just sitting on the sidelines for too long, you WILL miss out.
- Forums
- ASX - By Stock
- AVH
- Webinar
Webinar, page-34
-
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVH (ASX) to my watchlist
|
|||||
Last
$2.76 |
Change
0.130(4.94%) |
Mkt cap ! $187.9M |
Open | High | Low | Value | Volume |
$2.74 | $2.77 | $2.66 | $1.044M | 382.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 980 | $2.74 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.76 | 10173 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 980 | 2.740 |
3 | 36189 | 2.700 |
1 | 10000 | 2.680 |
3 | 2022 | 2.630 |
1 | 2671 | 2.620 |
Price($) | Vol. | No. |
---|---|---|
2.760 | 10173 | 2 |
2.770 | 17029 | 3 |
2.780 | 1500 | 1 |
2.790 | 3162 | 1 |
2.800 | 2372 | 3 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
AVH (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online